Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Lapatinib|DRUG: Trastuzumab
Sponsor: Consorzio Oncotech
Collaborators: Clinical Research Technology S.r.l.